<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">120489</article-id><article-id pub-id-type="doi">10.23868/gc120489</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Antitumor effect of hybrid nanocomplexes containing nanoparticles of orthovanadates rare earth elements and cholesterol</article-title><trans-title-group xml:lang="ru"><trans-title>Противоопухолевое действие гибридных нанокомплексов, содержащих наночастицы ортованадатов редкоземельных элементов и холестерин</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Goltsev</surname><given-names>A. N</given-names></name><name xml:lang="ru"><surname>Гольцев</surname><given-names>А. Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Babenko</surname><given-names>N. N</given-names></name><name xml:lang="ru"><surname>Бабенко</surname><given-names>Н. Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gaevskaya</surname><given-names>Yu. A</given-names></name><name xml:lang="ru"><surname>Гаевская</surname><given-names>Ю. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chelombytko</surname><given-names>O. V</given-names></name><name xml:lang="ru"><surname>Челомбитько</surname><given-names>О. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bondarovich</surname><given-names>N. A</given-names></name><name xml:lang="ru"><surname>Бондарович</surname><given-names>Н. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dubrava</surname><given-names>T. G</given-names></name><name xml:lang="ru"><surname>Дубрава</surname><given-names>Т. Г</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ostankov</surname><given-names>M. V</given-names></name><name xml:lang="ru"><surname>Останков</surname><given-names>М. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dimitrov</surname><given-names>A. Yu</given-names></name><name xml:lang="ru"><surname>Димитров</surname><given-names>А. Ю</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Klochkov</surname><given-names>V. K</given-names></name><name xml:lang="ru"><surname>Клочков</surname><given-names>В. К</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kavok</surname><given-names>N. S</given-names></name><name xml:lang="ru"><surname>Кавок</surname><given-names>Н. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Malyukin</surname><given-names>Yu. V</given-names></name><name xml:lang="ru"><surname>Малюкин</surname><given-names>Ю. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute for Problems of Cryobiology and Cryomedicine of the NAS of Ukraine</institution></aff><aff><institution xml:lang="ru">Институт проблем криобиологии и криомедицины НАН Украины</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute for Scintillation Materials of the NAS of Ukraine</institution></aff><aff><institution xml:lang="ru">Институт сцинтиляционных материалов НАН Украины</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2015-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2015</year></pub-date><volume>10</volume><issue>2</issue><issue-title xml:lang="en">VOL 10, NO2 (2015)</issue-title><issue-title xml:lang="ru">ТОМ 10, №2 (2015)</issue-title><fpage>54</fpage><lpage>60</lpage><history><date date-type="received" iso-8601-date="2023-01-05"><day>05</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2015, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2015, Эко-Вектор</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/120489">https://genescells.ru/2313-1829/article/view/120489</self-uri><abstract xml:lang="en"><p>An actual task of current oncology is the search for the structures, enabling to selectively affect the tumor stem cells, on the expansion rate of those the activity of oncologic process depends. Perspective in this aspect is the use of nanostructures selectively recognizing and inactivating tumor stem cells. In the research there was studied the effect of synthesized hybrid nanocomplexes based on nanoparticles of rare earth orthovanadates GdYV04:Eu3+, cholesterol and hydrophobic luminescent stain Dil on functional activity of Ehrlich carcinoma cells and expression in them of nanog, oct-4, sox-2 genes After pre-treatment of Ehrlich carcinoma cells with nanocomplexes there was shown an inhibition of tumor growth in vivo due to inactivation of the most carcinogenic CD44hi cells, which was accompanied with the reduced expression rate of the studied genes in total pool of cells The findings contribute to the understanding of the effect mechanisms of orthovanadates and open the prospects to apple new forms of nanocomposites in treatment of oncology diseases</p></abstract><trans-abstract xml:lang="ru"><p>Актуальной задачей современной онкологии является поиск структур, которые способны целенаправленно воздействовать на стволовые клетки опухоли, от полноты экспансии которых зависит активность онкопроцесса. Перспективным в этом плане является использование наноструктур, селективно распознающих и инактивирующих стволовые клетки опухоли. В работе исследовано влияние синтезированных гибридных нанокомплексов, содержащих наночастицы ортованадатов редкоземельных элементов GdYV04:Eu3+, холестерина и гидрофобного люминесцентного красителя Dil на функциональную активность клеток аденокарциномы Эрлиха и экспрессию в них генов nanog, oct-4, sox-2. После предобработки нанокомплексами клеток аденокарциномы Эрлиха показано ингибирование роста опухоли in vivo за счет инактивации наиболее канцерогенных CD44hi-клеток, что сопровождалось снижением степени экспрессии изученных генов в общем пуле клеток опухоли Полученные данные вносят вклад в понимание механизмов действия ортованадов и открывают перспективы применения новых форм нанокомпозитов в лечении онкологических заболеваний</p></trans-abstract><kwd-group xml:lang="en"><kwd>cancer stem cells</kwd><kwd>Ehrlich carcinoma</kwd><kwd>nanocomplexes</kwd><kwd>orthvanadates</kwd><kwd>cholesterol</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>стволовые опухолевые клетки</kwd><kwd>аденокарцинома Эрлиха</kwd><kwd>нанокомплексы</kwd><kwd>ортованадаты</kwd><kwd>холестерин</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ambasta R.K., Sharma A., Kumar P. Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy Vasc Cell. 2011; 3: 26.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Evangelou A.M. Vanadium in cancer treatment. Crit. Rev. 0ncol. Hematol. 2002; 42 (3): 249-65.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kopf-Maier P, Krahl D. Tumor inhibition by metallocenes: ultrastructural localisationof titanium and vanadium, in treated tumor cells by electron energy loss spectroscopy. Chem. Biol. interact. 1983; 44(3): 317-28.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Клочков В.К. Інститут сцинтиляційних матеріалів НАН України, власник. Спосі6 отримання водної дисперсії холестерину. Патент Украины 10801. 10. 03. 2015.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Al - Jarallah A., Trigatti B.L. A role for the scavenger receptor, class B type i in high density lipoprotein dependent activation of cellular signaling pathways. Biochim Biophys Acta. 2010; 1801(12): 1239-48.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Гольцев А.Н., Бабенко Н.Н., Гаевская Ю.А. и др. Идентификация опухолевых клеток гибридными комплексами на основе неорганических наночастиц и органических биологически активных соединений. Сб. статей 16-й Междунар. научн.-практ. конференции «Фундаментальные и прикладные исследования, разработка и применение высоких технологий в промышленности и экономике», 5-6 декабря 2013 г., СПб.: Изд-во Политех. ун-та, 2013. С. 121-31.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ozaslan M., Karagoz I.D., Kilic I.H. et al. Ehrlich ascites carcinoma. African J. Biotech. 2011; 10(13): 2375-78.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Al-Hajj M., Wicha M.S., Benito-Hernandez A. et al. Prospective identification of tumorigenic breast cancer cells. PNAS USA 2003; 100 (7): 3983-8.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ponti D., Costa A., Zaffaroni N. et al. isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65: 5506-11.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Jaggupilli A., Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin. Dev. immunol. 2012; 2012: 708036.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ghebeh H., Sleiman G.M., Manogaran P.S. et al. Profiling of normal and malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers. BMC Cancer 2013; 13: 289</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Chaffer C.L., Brueckmann I., Scheel C. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. PNAS USA 2011; 108: 7950-5.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Goltsev A.N., Chelombytko O.V., Bondarovich N.A. et al. Cryopreservation effect on pluripotency gene expression in Ehrlich carcinoma cells cells: Abstracts of Annual Scientific Conference &amp; AGM of the Society for Low Temperature Biology (STBL) «Freezing biological time 50th Anniversary Celebration» London, UK, October 8-10, 2014. P. 84.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Shipitsin M., Campbell L.L., Argani P., et al. Molecular definition of breast tumor heterogeneity Cancer Cell 2007; 11: 259-73</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ezeh U.I., Turek P.J., Reijo R.A. et al. Human embryonic stem cell genes 0CT4, NAN0G, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005; 104: 2255-65.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kumar S.M., Liu S., Lu H. et al. Acquired cancer stem cell phenotypes through 0ct4-mediated dedifferentiation. Oncogene 2012; 31: 4898-911.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Wang M.L., Chiou S.H., Wu C.W. Targeting cancer stem cells: emerging role of Nanog transcription factor 0nco Targets Ther 2013; 4 (6): 1207-20.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Гольцев А.М., Сафранчук О.В., Бондарович М.О. та інш. Мєтодичні підходи до стабілізації структурного і функціонального станів кріоконсервованих клітин аденокарциноми Ерліха. Доповіді Національної академії наук України. 2012; (8): 115-22.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Клочков В.К. Водные коллоидные растворы нанолюминофоров nReV04:Eu3+ (Re = Y, Gd, La). Наноструктурное материаловедение 2009; (2): 3-8</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Livak K.J., Schmittgen Th.D. Analysis of relative gene expression data Using real-time quantitative PCR and the 2-AACt method. Methods 2001; 25: 402-8.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Betker J.L., Kullberg M., Gomez J. et al. Cholesterol domains enhance transfection. Ther. Deliv. 2013; 4(4): 453-62.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Гольцев А.Н., Бабенко Н.Н., Гаевская Ю.А. и др. Способность наночастиц на основе ортованадатов к идентификации in vitro и ингибиции in vivo стволовых раковых клеток Наносистемы, наноматериалы, нанотехнологии 2013; 11(4): 729-39.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Leung E.L., Fiscus R.R., Tung J.W. et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties PLoS 0ne 2010; 19 (5): 11-9.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Korkaya H., Paulson A., Charafe-Jauffret E. et al. Regulation of mam-mary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009; 7 (6): 100-21.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Matsuda S., Nakanishi A., Wada Y. et al. Roles of Pi3K/AKT/ PTEN Pathway as a target for pharmaceutical therapy 0pen Med Chem. J. 2013; 7: 23-9.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Cooper D.L., Dougherty G.J. To metastasize or not - selection of CD44 splice sites Nat Med 1995; 1: 95-7</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Williams D.A., Cancelas J. A. Leukaemia: niche retreats for stem cells. Nature 2006; 444(7121): 827-8.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Bourguignon L.Y.W., Peyrollier K., Xia W. et al. Hyaluronan-CD44 interaction activates stem cell marker nanog, stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J. Biol. Chem. 2008; 283(25): 17635-51.</mixed-citation></ref></ref-list></back></article>
